Loading clinical trials...
Loading clinical trials...
A Phase I/II, Randomised, Controlled Study to Assess the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Adults (Phase I) and to Healthy Adolescents and Adults (Phase II)
Conditions
Interventions
MenABCWY-2Gen low dose vaccine
MenABCWY-2Gen high dose vaccine
+3 more
Locations
53
United States
GSK Investigational Site
Colorado Springs, Colorado, United States
GSK Investigational Site
Longmont, Colorado, United States
GSK Investigational Site
Doral, Florida, United States
GSK Investigational Site
Miami Lakes, Florida, United States
GSK Investigational Site
Meridian, Idaho, United States
GSK Investigational Site
Nampa, Idaho, United States
Start Date
June 14, 2021
Primary Completion Date
February 2, 2024
Completion Date
February 2, 2024
Last Updated
May 31, 2025
NCT01962207
NCT00508261
NCT01755689
NCT00974363
NCT00126984
NCT00196963
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions